Systematic review: the efficacy of treatments for irritable bowel syndrome – a European perspective

Irritable bowel syndrome (IBS) is a common, chronic disorder, characterized by abdominal pain/discomfort, bloating and altered bowel habit.

[1]  S. Gaarder,et al.  TREATMENT FOR IRRITABLE BOWEL SYNDROME , 2005, American family physician.

[2]  Y. Lacasse,et al.  From the authors , 2005, European Respiratory Journal.

[3]  F. Mearin,et al.  Bowel Habit Subtypes and Temporal Patterns in Irritable Bowel Syndrome: Systematic Review , 2005, The American Journal of Gastroenterology.

[4]  N. D. de Wit,et al.  Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. , 2005, The Cochrane database of systematic reviews.

[5]  M. Fallon.  Mechanisms of pulmonary vascular complications of liver disease: hepatopulmonary syndrome. , 2005, Journal of clinical gastroenterology.

[6]  B. Bonaz,et al.  Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial , 2005, Alimentary pharmacology & therapeutics.

[7]  D. Sanders,et al.  The Incidence of Self-prescribed Oral Complementary and Alternative Medicine Use by Patients With Gastrointestinal Diseases , 2005, Journal of clinical gastroenterology.

[8]  J. Davies,et al.  Randomised-controlled trial of a fibre supplement on the symptoms of irritable bowel syndrome , 2005, The journal of the Royal Society for the Promotion of Health.

[9]  A. Blum,et al.  Meta‐analysis: the treatment of irritable bowel syndrome , 2004, Alimentary pharmacology & therapeutics.

[10]  W. Chey,et al.  Long-Term Safety and Efficacy of Alosetron in Women with Severe Diarrhea-Predominant Irritable Bowel Syndrome , 2004, The American Journal of Gastroenterology.

[11]  R. Herings,et al.  Treatment patterns and health care costs of mebeverine‐treated IBS patients: a case‐control study , 2004, Pharmacoepidemiology and drug safety.

[12]  A. Lembo.  Irritable Bowel Syndrome Medications Side Effects Survey , 2004, Journal of clinical gastroenterology.

[13]  B. Bonaz,et al.  Irritable bowel syndrome in France: a common, debilitating and costly disorder , 2004, European journal of gastroenterology & hepatology.

[14]  A. Zinsmeister,et al.  Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[15]  S. Caras,et al.  CILANSETRON IN IRRITABLE BOWEL SYNDROME WITH DIARRHEA PREDOMINANCE (IBS-D): EFFICACY AND SAFETY IN A 3 MONTH US STUDY , 2004 .

[16]  T. Arranz,et al.  Effects of a high-fiber diet on symptoms of irritable bowel syndrome: a randomized clinical trial. , 2004, Nutrition.

[17]  K. Olden,et al.  Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  G. Smith,et al.  A comparison of irritable bowel syndrome patients managed in primary and secondary care: the Episode IBS study. , 2004, The British journal of general practice : the journal of the Royal College of General Practitioners.

[19]  Margaret M Heitkemper,et al.  Self-management for women with irritable bowel syndrome. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[20]  W. Kruis,et al.  Cisapride treatment of constipation–predominant irritable bowel syndrome is not superior to placebo , 2004, Journal of gastroenterology and hepatology.

[21]  A. Chawla,et al.  Absenteeism among employees with irritable bowel syndrome. , 2004, Managed care interface.

[22]  H. Mardini,et al.  Paroxetine to Treat Irritable Bowel Syndrome Not Responding to High-Fiber Diet: A Double-Blind, Placebo-Controlled Trial , 2004, American Journal of Gastroenterology.

[23]  R. Pandey,et al.  Yogic Versus Conventional Treatment in Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Control Study , 2004, Applied psychophysiology and biofeedback.

[24]  E. Björnsson,et al.  Treatment With Hypnotherapy Reduces the Sensory and Motor Component of the Gastrocolonic Response in Irritable Bowel Syndrome , 2004, Psychosomatic medicine.

[25]  I. Holme,et al.  A double‐blind, placebo‐controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome , 2004, Scandinavian journal of gastroenterology.

[26]  E. Mayer,et al.  Alosetron and irritable bowel syndrome , 2003, Expert opinion on pharmacotherapy.

[27]  N. Talley,et al.  A randomized controlled trial of cognitive behavior therapy, relaxation training, and routine clinical care for the irritable bowel syndrome , 2003, American Journal of Gastroenterology.

[28]  P. Whorwell,et al.  Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome , 2003, Alimentary pharmacology & therapeutics.

[29]  R. Kerstens,et al.  Prucalopride Is Effective in Patients with Severe Chronic Constipation in Whom Laxatives Fail to Provide Adequate Relief , 2003, Digestion.

[30]  H. Yuen,et al.  An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome , 2003, Gut.

[31]  G. Boeckxstaens,et al.  The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[32]  H. Birnbaum,et al.  The economic consequences of irritable bowel syndrome: a US employer perspective. , 2003, Archives of internal medicine.

[33]  G. Martin,et al.  Randomized Controlled Trial of Cognitive–Behavioral Group Therapy for Irritable Bowel Syndrome in a Medical Setting , 2003, Journal of Clinical Psychology in Medical Settings.

[34]  P. Whorwell,et al.  The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40 000 subjects , 2003, Alimentary pharmacology & therapeutics.

[35]  A. Zinsmeister,et al.  A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. , 2003, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[36]  N. Read,et al.  The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. , 2003, Gastroenterology.

[37]  Henry C. Lin,et al.  Normalization of Lactulose Breath Testing Correlates With Symptom Improvement in Irritable Bowel Syndrome: A Double-Blind, Randomized, Placebo-Controlled Study , 2003, American Journal of Gastroenterology.

[38]  M. Camilleri,et al.  Efficacy of alosetron in irritable bowel syndrome: a meta‐analysis of randomized controlled trials , 2003, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

[39]  A. Morselli-Labate,et al.  Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome , 2002, European journal of gastroenterology & hepatology.

[40]  S. Müller-lissner,et al.  Irritable bowel syndrome in Germany. A cost of illness study , 2002, European journal of gastroenterology & hepatology.

[41]  P. Schoenfeld,et al.  An evidence-based approach to the management of irritable bowel syndrome in North America , 2002 .

[42]  M. Lefkowitz,et al.  A randomized, double‐blind, placebo‐controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation , 2002, Alimentary pharmacology & therapeutics.

[43]  J. Rhodes,et al.  Naloxone treatment for irritable bowel syndrome — a randomized controlled trial with an oral formulation , 2002, Alimentary pharmacology & therapeutics.

[44]  R. Lazzara,et al.  Spontaneous Adverse Event Reports of Serious Ventricular Arrhythmias, QT Prolongation, Syncope, and Sudden Death in Patients Treated with Cisapride , 2002, Journal of cardiovascular pharmacology and therapeutics.

[45]  M. Lefkowitz,et al.  Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms. , 2002 .

[46]  W. Whitehead,et al.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? , 2002, Gastroenterology.

[47]  W. Rathmann,et al.  Prevalence of Functional Bowel Disorders and Related Health Care Seeking: A Population-Based Study , 2002, Zeitschrift fur Gastroenterologie.

[48]  B. Birkenfeld,et al.  A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome , 2001, European journal of gastroenterology & hepatology.

[49]  F. Pace,et al.  Tegaserod, a 5‐HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation , 2001, Alimentary pharmacology & therapeutics.

[50]  P. Jhingran,et al.  Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome , 2001, American Journal of Gastroenterology.

[51]  M. Camilleri,et al.  A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. , 2001, Archives of internal medicine.

[52]  T. Poynard,et al.  Meta‐analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome , 2001, Alimentary pharmacology & therapeutics.

[53]  A. Zinsmeister,et al.  Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. , 2001, Gastroenterology.

[54]  A. Forbes,et al.  Hypnotherapy and therapeutic audiotape: effective in previously unsuccessfully treated irritable bowel syndrome? , 2000, International Journal of Colorectal Disease.

[55]  Foster,et al.  Alosetron, a 5‐HT3 receptor antagonist, delays colonic transit in patients with irritable bowel syndrome and healthy volunteers , 2000, Alimentary pharmacology & therapeutics.

[56]  H. Mönnikes,et al.  The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome , 2000, American Journal of Gastroenterology.

[57]  P. Whorwell,et al.  Tegaserod has a favorable safety & tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome (IBS) , 2000 .

[58]  M. Camilleri,et al.  Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial , 2000, The Lancet.

[59]  Schütz,et al.  A double‐blind, randomized, placebo‐controlled dose‐ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome , 2000, Alimentary pharmacology & therapeutics.

[60]  G. Holtmann,et al.  Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients , 1999, Alimentary pharmacology & therapeutics.

[61]  A R Zinsmeister,et al.  esign of Treatment Trials for Functional Gastrointestinal isorders esign of Treatment Trials Committee : , 2006 .

[62]  D. Drossman,et al.  Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5‐HT3 receptor antagonist , 1999, Alimentary pharmacology & therapeutics.

[63]  K W Heaton,et al.  Functional bowel disorders and functional abdominal pain , 1999, Gut.

[64]  D. Podolsky.  Having an impact: Gastroenterology—the journal , 1999 .

[65]  T. Galovski,et al.  The Treatment of Irritable Bowel Syndrome with Hypnotherapy , 1998, Applied psychophysiology and biofeedback.

[66]  E. Blanchard,et al.  Controlled comparison of individual versus group cognitive therapy for irritable bowel syndrome , 1998 .

[67]  N. Talley,et al.  Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. , 1998, JAMA.

[68]  A. Francavilla,et al.  Otilonium bromide in irritable bowel syndrome: a double‐blind, placebo‐controlled, 15‐week study , 1998, Alimentary pharmacology & therapeutics.

[69]  M. Delvaux,et al.  Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome , 1998, Alimentary pharmacology & therapeutics.

[70]  G. Kurian,et al.  Symptom relief with amitriptyline in the Irritable Bowel syndrome , 1998, Journal of gastroenterology and hepatology.

[71]  F. Campbell,et al.  Effects of cisapride on symptoms and postcibal small-bowel motor function in patients with irritable bowel syndrome. , 1998, Scandinavian journal of gastroenterology.

[72]  Gran‐Hum Chen,et al.  Enteric-coated peppermint-oil capsules in the treatment of irritable bowel syndrome: A prospective, randomized trial , 1997, Journal of Gastroenterology.

[73]  K. Schütze,et al.  Double‐blind study of the effect of cisapride on constipation and abdominal discomfort as components of the irritable bowel syndrome , 1997, Alimentary pharmacology & therapeutics.

[74]  P. Whorwell,et al.  Selective 5‐hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia? , 1996, Alimentary pharmacology & therapeutics.

[75]  M. Gershwin,et al.  Treatment of irritable bowel syndrome with Lacteol Fort: a randomized, double-blind, cross-over trial. , 1996, The American journal of gastroenterology.

[76]  M. Kamm,et al.  Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). , 1996, Digestion.

[77]  M. Vatn,et al.  A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. , 1996, Scandinavian journal of gastroenterology.

[78]  M. Dapoigny,et al.  Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome , 1995, Digestive Diseases and Sciences.

[79]  E. Blanchard,et al.  A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. , 1995, Journal of consulting and clinical psychology.

[80]  H. Shepherd,et al.  Bran supplementation in the treatment of irritable bowel sgndrome , 1994, Alimentary pharmacology & therapeutics.

[81]  E. Blanchard,et al.  Cognitive therapy for irritable bowel syndrome. , 1994, Journal of consulting and clinical psychology.

[82]  E. Blanchard,et al.  Relaxation training as a treatment for irritable bowel syndrome , 1993, Biofeedback and self-regulation.

[83]  E. Guthrie,et al.  A Randomised Controlled Trial of Psychotherapy in Patients with Refractory Irritable Bowel Syndrome , 1993, British Journal of Psychiatry.

[84]  P. Toskes,et al.  Calcium polycarbophil compared with placebo in irritable bowel syndrome , 1993, Alimentary pharmacology & therapeutics.

[85]  A. Zinsmeister,et al.  Selective 5-hydroxytryptamine type 3 receptor antagonism with ondansetron as treatment for diarrhea-predominant irritable bowel syndrome: a pilot study. , 1992, Mayo Clinic proceedings.

[86]  A. Taylor,et al.  Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. , 1992, Behaviour research and therapy.

[87]  R. Prescott,et al.  Irritable bowel syndrome: assessment of psychological disturbance and its influence on the response to fibre supplementation. , 1992, Journal of psychosomatic research.

[88]  J. Boix,et al.  Aleatory clinical study comparing otilonium bromide with a fiber-rich diet in the treatment of irritable bowel syndrome. , 1991, The Italian journal of gastroenterology.

[89]  P. Casoli,et al.  Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. , 1991 .

[90]  R. Milo,et al.  "Prokinetic" treatment of constipation-predominant irritable bowel syndrome: a placebo-controlled study of cisapride. , 1991, Journal of clinical gastroenterology.

[91]  R. Mazumder,et al.  A comparison of mebeverine with high‐fibre dietary advice and mebeverine plus ispaghula in the treatment of irritable bowel syndrome: an open, prospectively randomised, parallel group study , 1990, The British journal of clinical practice.

[92]  A. Jalihal,et al.  Ispaghula therapy in irritable bowel syndrome: Improvement in overall well‐being is related to reduction in bowel dissatisfaction , 1990, Journal of gastroenterology and hepatology.

[93]  G. Bensi,et al.  Longterm treatment of irritable bowel syndrome with cimetropium bromide: a double blind placebo controlled clinical trial. , 1990, Gut.

[94]  M. Panijel,et al.  Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. A multicenter double-blind study , 1990 .

[95]  J. Fielding,et al.  The non-effect of pirenzepine in dietary resistant irritable bowel syndrome , 1989, Irish journal of medical science.

[96]  E. Zamble,et al.  A controlled behavioral treatment study of Irritable Bowel syndrome , 1989 .

[97]  R. E. Barry,et al.  INDIVIDUAL AND GROUP HYPNOTHERAPY IN TREATMENT OF REFRACTORY IRRITABLE BOWEL SYNDROME , 1989, The Lancet.

[98]  B. Imbimbo,et al.  Oral cimetropium bromide, a new antimuscarinic drug, for long-term treatment of irritable bowel syndrome. , 1988, The American journal of gastroenterology.

[99]  P. Whorwell,et al.  Double blind study of ispaghula in irritable bowel syndrome. , 1987, Gut.

[100]  G. Stein,et al.  Effects of desipramine on irritable bowel syndrome compared with atropine and placebo , 1987, Digestive Diseases and Sciences.

[101]  A. Dawson,et al.  Is bran efficacious in irritable bowel syndrome? A double blind placebo controlled crossover study. , 1987, Gut.

[102]  Tudor Gj.  A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome. , 1986 .

[103]  G. J. Tudor.  A general practice study to compare alverine citrate with mebeverine hydrochloride in the treatment of irritable bowel syndrome , 1986, The British journal of clinical practice.

[104]  P. Bennett,et al.  A comparison of psychological and medical treatment of the irritable bowel syndrome. , 1985, The British journal of clinical psychology.

[105]  J. R. Andersen,et al.  The effect of coarse wheat bran in the irritable bowel syndrome. A double-blind cross-over study. , 1985, Scandinavian journal of gastroenterology.

[106]  P. Whorwell,et al.  CONTROLLED TRIAL OF HYPNOTHERAPY IN THE TREATMENT OF SEVERE REFRACTORY IRRITABLE-BOWEL SYNDROME , 1984, The Lancet.

[107]  S. Larsen,et al.  A double-blind study of the effect of trimipramine in patients with the irritable bowel syndrome. , 1984, Scandinavian journal of gastroenterology.

[108]  D. Barends,et al.  Role of loperamide and placebo in management of irritable bowel syndrome (IBS) , 1984, Digestive Diseases and Sciences.

[109]  N. Read,et al.  Oral domperidone: double blind comparison with placebo in irritable bowel syndrome. , 1983, Gut.

[110]  J. Svedlund,et al.  CONTROLLED STUDY OF PSYCHOTHERAPY IN IRRITABLE BOWEL SYNDROME , 1983, The Lancet.

[111]  J. Fielding,et al.  Double blind trial of ispaghula/poloxamer in the Irritable Bowel Syndrome. , 1983, Irish medical journal.

[112]  S. Larsen,et al.  The effect of trimipramine in patients with the irritable bowel syndrome. A double-blind study. , 1982, Scandinavian journal of gastroenterology.

[113]  S. Mishra,et al.  Role of ispaghula husk in the management of irritable bowel syndrome (a randomized double-blind crossover study). , 1982, The Journal of the Association of Physicians of India.

[114]  P. Wong,et al.  Therapeutic Usefulness of Amitriptyline in Spastic Colon Syndrome , 1982, International journal of psychiatry in medicine.

[115]  D. D. Fox,et al.  Psyllium therapy in the irritable bowel syndrome. A double-blind trial. , 1981, Annals of internal medicine.

[116]  G. Dirnberger,et al.  Treatment of the irritable bowel syndrome with Bentyl (dicyclomine hydrochloride). , 1981 .

[117]  M. Farthing.  Treatment of irritable bowel syndrome , 1981, BMJ : British Medical Journal.

[118]  Fielding Jf.  Double blind trial of trimebutine in the irritable bowel syndrome. , 1980 .

[119]  S. Truelove,et al.  Treatment of irritable bowel syndrome with lorazepam, hyoscine butylbromide, and ispaghula husk. , 1979, British medical journal.

[120]  I. D. Wilson,et al.  Irritable colon and depression. , 1978, Psychosomatics.

[121]  K. Heaton,et al.  WHEAT FIBRE AND IRRITABLE BOWEL SYNDROME A Controlled Trial , 1977, The Lancet.

[122]  H. Wulff,et al.  A DOUBLE-BLIND TRIAL OF THE EFFECT OF WHEAT BRAN ON SYMPTOMS OF IRRITABLE BOWEL SYNDROME , 1976, The Lancet.

[123]  E. Ehrenpreis.  Constipation-Predominant Irritable Bowel Syndrome , 2006 .

[124]  M. Valdovinos,et al.  Un consenso latinoamericano sobre el síndrome del intestino irritable , 2004 .

[125]  P. Whorwell,et al.  Benefit-Risk Assessment of Tegaserod in Irritable Bowel Syndrome , 2004, Drug safety.

[126]  M. Valdovinos,et al.  [Latin-American consensus document on irritable bowel syndrome]. , 2004, Gastroenterologia y hepatologia.

[127]  P. Schoenfeld,et al.  Systematic review on the management of irritable bowel syndrome in North America , 2002, American Journal of Gastroenterology.

[128]  Evidence-based position statement on the management of irritable bowel syndrome in North America , 2002, American Journal of Gastroenterology.

[129]  P. Farup,et al.  The symptomatic effect of cisapride in patients with irritable bowel syndrome and constipation. , 1998, Scandinavian journal of gastroenterology.

[130]  R. Awad,et al.  Irritable bowel syndrome treatment using pinaverium bromide as a calcium channel blocker. A randomized double-blind placebo-controlled trial. , 1995, Acta gastroenterologica Latinoamericana.

[131]  R. Newell,et al.  Behavioural psychotherapy in the treatment of irritable bowel syndrome. , 1991, Journal of psychosomatic research.

[132]  G Shaw,et al.  Stress management for irritable bowel syndrome: a controlled trial. , 1991, Digestion.

[133]  F. Baldi,et al.  Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. , 1991, The Italian journal of gastroenterology.

[134]  I. Cook,et al.  Effect of dietary fiber on symptoms and rectosigmoid motility in patients with irritable bowel syndrome. A controlled, crossover study. , 1990, Gastroenterology.

[135]  N. Hovdenak.  Loperamide treatment of the irritable bowel syndrome. , 1987, Scandinavian journal of gastroenterology. Supplement.

[136]  B. Imbimbo,et al.  Long-term treatment of irritable bowel syndrome with cimetropium bromide, a new antimuscarinic compound , 1987 .

[137]  A. Nielsen,et al.  Loperamide in treatment of irritable bowel syndrome--a double-blind placebo controlled study. , 1987, Scandinavian journal of gastroenterology. Supplement.

[138]  G. Saponati,et al.  Single drug treatment for irritable colon: rociverine versus trimebutine maleate , 1986 .

[139]  B. Imbimbo,et al.  Double-blind study of a new antimuscarinic, cimetropium bromide, in patients with irritable bowel syndrome. , 1986, Clinical therapeutics.

[140]  J. Holl,et al.  Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. , 1986, Digestion.

[141]  J. Fielding.  Domperidone treatment in the irritable bowel syndrome. , 1982, Digestion.

[142]  K. Lüttecke.  A three-part controlled study of trimebutine in the treatment of irritable colon syndrome. , 1980, Current medical research and opinion.

[143]  R. Milo.  Use of the peripheral dopamine antagonist, domperidone, in the management of gastro-intestinal symptoms in patients with irritable bowel syndrome. , 1980, Current medical research and opinion.

[144]  J. Fielding.  Double blind trial of trimebutine in the irritable bowel syndrome. , 1980, Irish medical journal.

[145]  Irritable colon syndrome treated with an antispasmodic drug. , 1976, The Practitioner.